NCT01248247 - BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

334

Participants

Timeline

Start Date

June 2, 2011

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions

Lung Cancer

Interventions

DRUG

Erlotinib

150 mg by mouth each day of a 28 day cycle.

DRUG

AZD6244

100 mg by mouth daily of a 28 day cycle.

DRUG

MK-2206

100 mg by mouth every week of a 28 day cycle.

DRUG

Sorafenib

400 mg by mouth twice a day for a 28 day cycle.

DRUG

Erlotinib

150 mg by mouth daily of a 28 day cycle.

DRUG

MK-2206

135 mg by mouth every week of a 28 day cycle.

Trial Locations (2)

University of Texas MD Anderson Cancer Center, Houston

Yale Universtiy, New Haven